EUCTR2004-000703-18-IT进行中（未招募）不适用
A multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan respectively Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2. ASTRID Antihypertensive treatment of Systolic/diastolic hypertension comparing Teveten and Ramipril in type 2 Diabetics .
SOLVAY PHARMA0 个研究点目标入组 440 人开始时间: 2006年12月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 440
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan respectively Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 (ASTRID – Antihypertensive treatment of Systolic/diastolic hypertension comparing Teveten and Ramipril in type 2 Diabetics). - ASTRIDEUCTR2004-000703-18-ESSOLVAY PHARMACEUTICALS GMBH440
进行中（未招募）
不适用
A Multicenter, Double-blind, Randomized Study comparing the Safety and Tolerability of Iloprost inhalation solution delivered by I-neb utilizing Power disc-15 and Power disc-6 in Patients with Symptomatic Pulmonary Arterial Hypertension - PROWESS 15 ExtensioEUCTR2009-011013-24-ATActelion Pharmaceuticals Ltd.63
进行中（未招募）
不适用
A multicenter, randomized, double blind study comparing the clinical effects of intravenous montelukast with palcebo in patients with acute asthmaEUCTR2004-000614-39-ITMERCK SHARP DOHME550
进行中（未招募）
不适用
A multicenter, randomized, double-blind study with 2 groups as prove of concept for the treatment of ACE induced angioedema with subcutaneous Icatibant - AMACEThe study objective is to assess the efficacy and safety of the Bradykinin-2 (BK-2) receptor antagonist Icatibant compared to a historic group of 47 patients with ACE inhibitor induced angioedema which we have been previously treated in our centers with current standard” therapy (250 mg methylprednisolon and 2 mg clemastine).EUCTR2009-015410-22-DEMedizinische Fakultaet der Technischen Universitaet Muenchen30
进行中（未招募）
不适用
A double-blind, randomized, multi-center study with 500 mg QD of TRO19622 versus placebo in patients with painful peripheral diabetic neuropathyEUCTR2006-004545-42-LVTROPHOS180